Clinical Trial Update: Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

AEZS-108, a doxorubicin-GnRH agonist conjugate, completed Phase 1/2 testing in metastatic hormone-resistant prostate cancer. The trial was conducted by the Univ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• AEZS-108 (zoptarelin doxorubicin)

Snippet

Sponsor: University of Southern California | Conditions: Prostate Cancer, Hormone-resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED